Medicenna Therapeutics Corp (MDNA_TSE)
MDNA_TSE moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How MDNA_TSE actually reacts to news — the realized, point-in-time move the market made, measured across 127 labeled events over the last three years with zero look-ahead.
MDNA_TSE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 29% | 68 |
| 30-min | 0.00% | 46% | 74 |
| 60-min | +0.40% | 51% | 75 |
| to close | 0.00% | 48% | 77 |
| Middle 50% of MDNA_TSE reactions | -0.29% to +3.32% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 127 |
Half of all Medicenna Therapeutics Corp news events land between -0.29% and +3.32% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MDNA_TSE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MDNA_TSE's baseline. Nothing else.
Recent MDNA_TSE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026 | Press release | GlobeNewswire | — | — | |
| Medicenna Announces Results of Annual General and Special Meeting of Shareholders | Press release | GlobeNewswire | — | — | |
| Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting | Press release | GlobeNewswire | — | — | |
| Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights | Press release | GlobeNewswire | — | — | |
| Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms | Press release | GlobeNewswire | — | — | |
| Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 | Press release | GlobeNewswire | — | — | |
| Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs | Press release | GlobeNewswire | — | — | |
| Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet | Press release | GlobeNewswire | — | — | |
| Medicenna Announces the Finalization of the Terms of its Public Offering of Securities | Press release | GlobeNewswire | — | — | |
| Medicenna Announces the Launch of a Marketed Public Offering of Securities | Press release | GlobeNewswire | — | — | |
| Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma | Press release | GlobeNewswire | — | — | |
| Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026 | Press release | GlobeNewswire | — | — | |
| Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 | Press release | GlobeNewswire | — | — | |
| Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer | Press release | GlobeNewswire | — | — | |
| Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Announces Participation in Upcoming Conferences | Press release | GlobeNewswire | — | — | |
| Medicenna Announces Changes to Board Composition | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook | Press release | GlobeNewswire | — | — | |
| Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | — | — | |
| Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma | Press release | GlobeNewswire | — | — | |
| Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Announces Participation in Upcoming Conferences | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference | Press release | GlobeNewswire | — | — | |
| ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City | Press release | GlobeNewswire | — | — | |
| Medicenna Announces Results of Annual Meeting of Shareholders | Press release | GlobeNewswire | — | — | |
| Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | Press release | GlobeNewswire | — | — | |
| Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights | Press release | GlobeNewswire | — | — | |
| Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream | Press release | GlobeNewswire | — | — | |
| Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting | Press release | GlobeNewswire | — | — | |
| Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting | Press release | GlobeNewswire | — | — | |
| Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference | Press release | GlobeNewswire | — | — | |
| Medicenna to Present at Jones Healthcare and Technology Innovation Conference | Press release | GlobeNewswire | — | — | |
| Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting | Press release | GlobeNewswire | — | — | |
| Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update | Press release | GlobeNewswire | — | — | |
| Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | Press release | GlobeNewswire | — | — | |
| Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 | Press release | GlobeNewswire | — | — | |
| Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) | Press release | GlobeNewswire | — | — | |
| Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study | Press release | GlobeNewswire | — | — | |
| Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference | Press release | GlobeNewswire | — | — | |
| Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) | Press release | GlobeNewswire | — | — | |
| Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update | Press release | GlobeNewswire | — | — | |
| Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) | Press release | GlobeNewswire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MDNA_TSE section they belong to.
Where else MDNA_TSE is measured.
MDNA_TSE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) | 129 | +0.04% | 55% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 129 | -0.18% | 44% |
| OPGEN INC (OPGN) | 127 | 0.00% | 41% |
| Orgenesis Inc. (ORGS) | 127 | +0.01% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Medicenna Therapeutics Corp's median reaction calculated?
Every labeled MDNA_TSE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 127 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of MDNA_TSE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MDNA_TSE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.